The gastrointestinal (GI) tract is one of the most common organs affected by adverse drug reactions. While it is essential to assess GI toxicity early in drug development, traditional toxicity assays using model cell lines do not accurately reflect the human gut. Stem cell-based technologies that recreate the human intestine enable researchers to better evaluate drug-induced GI toxicity during candidate drug screening. In this webinar, experts from Altis Biosystems will discuss the latest advances of GI toxicity assessment empowered by stem cell and organ-on-a-chip technology.
Topics to be covered
- Challenges of assessing GI risk in drug development
- Assessing GI toxicity using an in vitro intestinal stem cell model
Viewers of the webinar will have an opportunity to apply for a free pilot project! Learn more about the pilot project https://www.altisbiosystems.com/pilot-project
Wednesday, July 27th, 2022 | 11:00 AM - 12:30 PM Eastern Time
This webinar will be available to view live and on demand.
Speakers
Bill Thelin, PhD
Chief Scientific Officer
Altis Biosystems
Bailey Zwarycz, PhD
Associate Director, Commercial Services
Altis Biosystems
